All In Biotech

Drug Trial Radar · NCT02226120

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

A Multicenter Study to Evaluate Safety and Tolerability in Patients With Chronic Heart Failure and Reduced Ejection Fraction From PARADIGM-HF Receiving Open Label LCZ696

Last checked: Nov 19, 2026Latest source record: Feb 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,980

Actual

Start

Oct 16, 2014

Primary completion

Dec 28, 2017

Study completion Dec 28, 2017

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 27, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to collect safety and tolerability data on LCZ696 in eligible PARADIGM-HF patients who received open-label investigational drug. The parent PARADIGM-HF (NCT01035255) trial was terminated early due to compelling efficacy of LCZ696 in patients with heart failure with reduced ejection fraction (HFrEF) after the final pre-specified interim analysis in March 2014.

Conditions

  • Chronic Heart Failure With Reduced Ejection Fraction

Interventions

  • LCZ696Drug

    Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths as a Measure of Safety and Tolerability of LCZ696Time frame: From first dose of study treatment to 30 days after last dose of study treatment, up to 30 months.

Locations

394 sites in 41 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Huntsville, Alabama

  • Novartis Investigative Site

    Muscle Shoals, Alabama

  • Novartis Investigative Site

    Little Rock, Arkansas

  • Novartis Investigative Site

    Oceanside, California

  • Novartis Investigative Site

    Palm Springs, California

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    Santa Rosa, California

  • Novartis Investigative Site

    Boynton Beach, Florida

  • Novartis Investigative Site

    Des Moines, Iowa

  • Novartis Investigative Site

    Covington, Louisiana

  • Novartis Investigative Site

    Columbia, Maryland

  • Novartis Investigative Site

    Saginaw, Michigan

  • Novartis Investigative Site

    Minneapolis, Minnesota

  • Novartis Investigative Site

    Fremont, Nebraska

  • Novartis Investigative Site

    New York, New York

  • Novartis Investigative Site

    Rosedale, New York

  • Novartis Investigative Site

    Raleigh, North Carolina

  • Novartis Investigative Site

    Marion, Ohio

  • Novartis Investigative Site

    Rapid City, South Dakota

  • Novartis Investigative Site

    Dallas, Texas

  • Novartis Investigative Site

    Dallas, Texas

  • Novartis Investigative Site

    Livingston, Texas

  • Novartis Investigative Site

    Spokane, Washington

  • Novartis Investigative Site

    Waukesha, Wisconsin

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Corrientes, Argentina

  • Novartis Investigative Site

    Formosa, Argentina

  • Novartis Investigative Site

    Formosa, Argentina

  • Novartis Investigative Site

    Mendoza, Argentina

  • Novartis Investigative Site

    San Luis, Argentina

  • Novartis Investigative Site

    Santa Fe, Argentina

  • Novartis Investigative Site

    Santa Fe, Argentina

  • Novartis Investigative Site

    Santiago del Estero, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Ciudad Autonoma de Bs As, Buenos Aires, Argentina

  • Novartis Investigative Site

    Mar del Plata, Buenos Aires, Argentina

  • Novartis Investigative Site

    Quilmes, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires F.D., Argentina

Showing 40 of 394 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.